Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Royce & Associates LP

Royce & Associates LP raised its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 11.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 339,529 shares of the specialty pharmaceutical company's stock after buying an additional 33,674 shares during the quarter. Royce & Associates LP owned approximately 1.05% of Collegium Pharmaceutical worth $9,728,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its position in shares of Collegium Pharmaceutical by 3.9% in the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock worth $67,459,000 after acquiring an additional 64,958 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Collegium Pharmaceutical by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company's stock valued at $29,974,000 after purchasing an additional 5,464 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Collegium Pharmaceutical by 17.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company's stock valued at $29,586,000 after buying an additional 116,327 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Collegium Pharmaceutical by 4.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 381,494 shares of the specialty pharmaceutical company's stock worth $14,741,000 after buying an additional 16,655 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Collegium Pharmaceutical by 173.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock worth $10,711,000 after buying an additional 175,892 shares during the last quarter.

Remove Ads

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Scott Dreyer sold 2,255 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $67,650.00. Following the sale, the executive vice president now directly owns 124,421 shares in the company, valued at approximately $3,732,630. This represents a 1.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the sale, the executive vice president now directly owns 154,204 shares in the company, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 109,193 shares of company stock valued at $3,243,594 in the last three months. Corporate insiders own 3.98% of the company's stock.

Collegium Pharmaceutical Stock Up 0.4 %

Collegium Pharmaceutical stock traded up $0.12 during midday trading on Friday, hitting $30.05. 2,287,750 shares of the company were exchanged, compared to its average volume of 417,801. The company has a market cap of $946.15 million, a PE ratio of 12.95 and a beta of 0.99. The company's fifty day moving average price is $30.69 and its 200-day moving average price is $32.71. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical, Inc. has a fifty-two week low of $27.28 and a fifty-two week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. On average, research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on COLL shares. Needham & Company LLC raised Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target for the company in a research report on Friday, January 10th. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Finally, Piper Sandler dropped their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $43.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.